Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q5T9L3

UPID:
WLS_HUMAN

ALTERNATIVE NAMES:
Integral membrane protein GPR177; Protein evenness interrupted homolog; Putative NF-kappa-B-activating protein 373

ALTERNATIVE UPACC:
Q5T9L3; B2RNT2; Q5JRS7; Q7Z2Z9; Q8NC43

BACKGROUND:
The Protein wntless homolog, or GPR177, is integral in the Wnt signaling pathway, affecting crucial developmental processes and cellular functions. It regulates the secretion and sorting of Wnt proteins, impacting cell fate decisions, proliferation, and organogenesis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Protein wntless homolog could open doors to potential therapeutic strategies for Zaki syndrome, characterized by developmental delay and dysmorphic features. Insights into its function may pave the way for novel interventions in diseases where Wnt signaling is implicated.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.